61	Please type a plus sign (+) insi	de this x→ 1
Ο,	Please type a plus sign (+) insi	de this x

Approval for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

Ī	RA	NS	MI	T	T	Αl	
		FO	RI	И			

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission | 12

Signature

Application Number	10/020,733	ਜ	
Filing Date	10/30/01	오	APR
First Named Inventor	Walke	NHR EN HR	R 2
Group Art Unit	1645	田1	2 21
Examiner Name	To be assigned	600/	2003
Attorney Docket Number	LEX-0263-USA	98	

			ΕN	ICLOSURES (check all that ap	ply)			
	Fee Transmi	ttal Form		Assignment Papers (for an Application)		After Allowance Communication to Group		
	Fee Attached			Drawing(s)		Appeal Communication to Board of Appeals and Interferences		
	Amendment / Reply			Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
	After Final			Petition		Proprietary Information		
	Affida	vits/declaration(s)		Petition to Convert to a Provisional Application		Status Letter		
	Extension of	Time Request		Power of Attorney, Revocation Change of Correspondence Address	$\boxtimes$	Other Enclosure(s) (please identify below):		
	Express Aba	ndonment Request		Terminal Disclaimer	PI	eturn postcard FO Form 1449 and 5 references		
$\times$	Supplemental Information Disclosure Statement			Request for Refund	l Int	ternational Search Report		
Certified Copy of Priority Document(s)				CD, Number of CD(s)				
Response to Missing Parts/ Incomplete Application				Remarks				
	☐ Respo	nse to Missing Parts		24231				
	1 1 '	37 CFR 1.52 or 1.53				O I ARK OFFICE		
<u></u>		SIC	MATL	IRE OF APPLICANT, ATTORNEY,	OR AG	ENT		
or	Firm  or Lance K. Ishimoto Reg. No. 41,866 Individual name Lexicon Genetics Incorporated							
Sign	Signature Line & Shenesta by Enoid W deller 1822 41,011							
Date	Date April 16, 2003							
OFFICIAL OF MAILING								
	CERTIFICATE OF MAILING							
mail i	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box DD, P.O. Box 2327, Arlington, VA  April 16, 2003  22202 on this date:							
Турес	d or printed na	me Nancy Stacey						
<b>-</b>								

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

Date

April 16, 2003



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke et al.	
Application No.: 10/020,733	APF ECH C
Filed: 10/30/01	Group Art Unit: 1645  Examiner: To Be Assigned 8
Title: Novel Human Proteases and Polynucleotides Encoding the Same	Group Art Unit: 1645  Examiner: To Be Assigned 00/2900
Attorney Docket No.: LEX-0263-USA	
Commissioner for Patents Arlington, VA 22202  SUPPLEMENTAL INFORMATION DISCLO	DSURE STATEMENT
Dear Sir:	
This Supplemental Information Disclosure Statemen	nt is submitted:
X under 37 CFR 1.97(b), or (Within three months of filing national applica application; or before mailing date of first offic occurs last)	
under 37 CFR 1.97(c) together with either a: Certification under 37 CFR 1.97(e), or a \$180.00 fee under 37 CFR 1.17(p), or (After the CFR 1.97(b) time period, but be allowance, whichever occurs first)	efore final action or notice of
under 37 CFR 1.97(d) together with a:  Certification under 37 CFR 1.97(e), and a petition under 37 CFR 1.97(d)(2)(ii), and a \$130.00 petition fee set forth in 37 CFR (Filed after final action or notice of allows payment of the issue fee)	1.17(i)(1).
T	

X Applicant(s) submit herewith Form PTO 1449-Supplemental Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references are that they were cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

April 16, 2003

Date

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED (281) 863-3333

Substituted form 1449B/PTO

APR 2 1 2003 SUPPLEMENTAL

INFORMATION DISCLOSURE

STANDEMENT BY APPLICANT

Sheet 2 of 2

Complete if Known

Application Number 10/020,733

Filing Date 10/30/01

First Named Inventor Walke

Group Art Unit 1645

Examiner Name To be assigned

Attorney Docket Number LEX-0263-USA

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CL	Fritsche, J. et al., "Molecular cloning and characterization of a human metalloprotease disintegrin - a noval marker for dendritic cell differentiation," 07/15/00, Blood, Vol. 96, No. 2, pgs. 732-739, XP001119962.	
	СМ	Database EMBL 'Online', ADAM gene 2, 03/20/01, RUBEN et al., retrieved from EMBL, Database accession no. AAC91177, XP002236360, abstract.	
	CN	WEI, P. et al., "Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta," 01/26/01, Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL, Vol. 280, No. 3, pgs. 744-755, XP001120634, ISSN: 0006-291X.	
		International Search Report, International Application No. PCT/US01/48498, 10/30/01 (Attorney Docket No. LEX-0263-PCT)	
		至 A A	-
		$\mathbb{H}^{\mathbb{R}^n}$	
		<b> </b>	
		60 N3 H	
		8	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → □

PTO/SB/08A (10-96)
Proved for use through 10/31/99. OMB 0651-0031
Patent and T

ń	per the Riper	Work Reduction Act of 1995	. no pe	re required to rest	oond to a collection of information unle	ss it o vs a valid OMB control number.		
	Substitut	e for 10 m 1449A/PTO			Complete if Known			
A	PR 2 1 20	® SUPPLEM			Application Number	10/020,733		
•	,	~ SUPPLEM	EN.	TAL	Filing Date	10/30/01		
'n	INFO	RMATION DI	ISC	LOSURE	First Named Inventor	Walke		
<	E PLANTAL			LUCUIL	Group Art Unit	1645		
	STAT	EMENI BY	<u>API</u>	PLICANI	Examiner Name	To be assigned		
	Sheet	1	of	2	Attorney Docket Number	LEX-0263-USA		

				U.S. PATENT DOCUMEN	TS	
	Cite	U.S. Patent		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines, Where Relevant
	No.¹	Number	Kind Code <sup>2</sup> ( <i>if known</i> )	of Cited Document	of cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
			<del></del>			<del></del>
						<del>2</del> , <u>1</u>
						0 7 7
			++			
	·					
	_					
						<del>- 65 €</del> - F
						7.5
						990
<b> </b>						
		· · · · · · · · · · · · · · · · · · ·				
			<del>-   -  </del>			

				FORE	IGN PATENT DOCUMENTS		•	
Examiner (	Cite		Foreign Patent Docu	ument	Name of Patentee or Applicant	Date of	Pages, Columns, Lines,	T
Initials*	No.¹	Office	e³ Number⁴	Kind Code <sup>s</sup> ( <i>if known</i> )	of Cited Document	Publication of cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵
	Cl	wo	97/09420	A2	Celltech Therapeutics Ltd.	03/13/97		
	СК	wo	00/73323	A2	Human Genome Sciences Inc	12/07/00		
				I				

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.